201: The MIS-Cery of COVID-19: The Diagnostic Conundrum of MIS-C in Sickle Cell Anemia

Seamon, Keri; Zelinka, Kailea; Mathew, Smitha; Cagle, William

doi:10.1097/01.ccm.0000726692.24514.09

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our registry, all four SCD patients with MIS‐C were critically ill. Descriptions of MIS‐C in SCD patients are limited to case reports and series, including one describing successful use of complement blockade with eculizumab in patients with thrombotic microangiopathy due to acute COVID‐19 or MIS‐C 16,19,20 . SCD causes endothelial damage and derangements in multiple thrombo‐inflammatory pathways, including abnormal activation of the complement system 21 .…”

Section: Discussionmentioning

confidence: 99%

“…Descriptions of MIS-C in SCD patients are limited to case reports and series, including one describing successful use of complement blockade with eculizumab in patients with thrombotic microangiopathy due to acute COVID-19 or MIS-C. 16,19,20 SCD causes endothelial damage and derangements in multiple thrombo-inflammatory pathways, including abnormal activation of the complement system. 21 The terminal complement cascade is also activated in pediatric patients with severe COVID-19 and MIS-C. 22 Clinical outcomes later than Day 28 of illness were not collected, leading to potential omission of MIS-C cases presenting after Day 28.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Description of a national, multi‐center registry of patients with sickle cell disease and SARS‐CoV‐2 infection: Data from the Pediatric COVID‐19 United States Registry

Dain,

Diorio,

Fisher

et al. 2024

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Children with sickle cell disease (SCD) are at risk of complications from viral infections, including SARS‐CoV‐2. We present the clinical characteristics and outcomes of pediatric patients with SCD from the Pediatric COVID‐19 United States Registry who developed acute COVID‐19 due to SARS‐CoV‐2 infection (n = 259) or multisystem inflammatory syndrome in children (MIS‐C; n = 4). Nearly half of hospitalized children with SCD and SARS‐CoV‐2 infection required supplemental oxygen, though children with SCD had fewer intensive care (ICU) admissions compared to the general pediatric and immunocompromised populations. All registry patients with both SCD and MIS‐C required ICU admission. Children with SCD are at risk of severe disease with SARS‐CoV‐2 infection, highlighting the importance of vaccination in this vulnerable population.

show abstract

Section: Discussionmentioning

confidence: 99%